All In Biotech

Drug Trial Radar · NCT02553317

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Last checked: Nov 20, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 145 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

145

Actual

Start

Nov 2015

Primary completion

Aug 2017

Study completion Aug 2017

Sponsor

Lead sponsor
Ablynx, a Sanofi companyIndustry
Sponsor type
Industry
First posted
Sep 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis

Conditions

  • Acquired Thrombotic Thrombocytopenic Purpura

Interventions

  • CaplacizumabBiological

    * First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day. * Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE. * Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression.

  • PlaceboBiological

    * First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day. * Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE. * Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Platelet Count ResponseTime frame: Only data from the DB daily PE period (median = 5 days) up to the cut-off were used. The cut-off point was defined by whichever occured first: 1) 45 days of daily PE after start of study drug, 2) stop of daily PE, 3) stop of study drug (median = 34 days)

Locations

101 sites in 16 countries. Site status is shown where the registry gives one.

  • Investigator Site

    Birmingham, Alabama

  • Investigator Site

    Los Angeles, California

  • Investigator Site

    Atlanta, Georgia

  • Investigator Site

    Boston, Massachusetts

  • Investigator Site

    St Louis, Missouri

  • Investigator Site

    Rochester, New York

  • Investigator Site

    Rochester, New York

  • Investigator Site

    Valhalla, New York

  • Investigator Site

    Chapel Hill, North Carolina

  • Investigator Site

    Durham, North Carolina

  • Investigator Site

    Winston-Salem, North Carolina

  • Investigator SIte

    Cleveland, Ohio

  • Investigator Site

    Columbus, Ohio

  • Investigator Site

    Oklahoma City, Oklahoma

  • Investigator Site

    Pittsburgh, Pennsylvania

  • Investigator Site

    Charleston, South Carolina

  • Investigator Site

    Greenville, South Carolina

  • Investigator Site

    Houston, Texas

  • Investigator Site

    Salt Lake City, Utah

  • Investigator Site

    Brisbane, Australia

  • Investigator Site 1

    Melbourne, Australia

  • Investigator Site 2

    Melbourne, Australia

  • Investigator Site 3

    Melbourne, Australia

  • Investigator Site 4

    Melbourne, Australia

  • Investigator Site 5

    Melbourne, Australia

  • Investigator Site

    Perth, Australia

  • Investigator Site 1

    Sydney, Australia

  • Investigator Site 2

    Sydney, Australia

  • Investigator Site

    Vienna, Austria

  • Investigator Site

    Antwerp, Belgium

  • Investigator Site

    Brussels, Belgium

  • Investigator Site

    Haine-Saint-Paul, Belgium

  • Investigator Site

    La Louvière, Belgium

  • Investigator Site

    Leuven, Belgium

  • Investigator Site

    London, Canada

  • Investigator Site

    Toronto, Canada

  • Invesigator Site

    Montreal, Quebec, Canada

  • Investigator Site

    Brno, Czechia

  • Investigator Site

    Hradec Králové, Czechia

  • Investigator Site

    Olomouc, Czechia

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.